First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened?
Burtness B. First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened? Journal Of Clinical Oncology 2023, 41: 2134-2137. PMID: 36877893, DOI: 10.1200/jco.22.02349.Peer-Reviewed Original Research